{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:14:59Z","timestamp":1738386899131,"version":"3.35.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[1989,7,1]],"date-time":"1989-07-01T00:00:00Z","timestamp":615254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1989,7,1]],"date-time":"1989-07-01T00:00:00Z","timestamp":615254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1989,7]]},"DOI":"10.1136\/ard.48.7.539","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T23:49:46Z","timestamp":1217288986000},"page":"539-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment."],"prefix":"10.1016","volume":"48","author":[{"given":"H","family":"Bliddal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Eiberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Helin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Svejgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/bmj.280.6230.1498","article-title":"Adverse reactions to Dpenicillamine after gold toxicity","volume":"280","author":"J, Dodd M.; D, Griffiths I.; M, Thompson","year":"1980","unstructured":"Dodd M J, Griffiths I D, Thompson M. Adverse reactions to Dpenicillamine after gold toxicity. Br MedJ 1980; 280: 1498-500.","journal-title":"Br MedJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/bmj.285.6342.595","article-title":"Influence of previous gold toxicity on subsequent development of penicillamine toxicity","volume":"285","author":"J, Smith P.; R, Swinburn W.; R, Swinson D.; M, Stewart I.","year":"1982","unstructured":"Smith P J, Swinburn W R, Swinson D R, Stewart I M. Influence of previous gold toxicity on subsequent development of penicillamine toxicity. Br Med J 1982; 285: 595-6.","journal-title":"Br Med J"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1399-0039.1985.tb00932.x","article-title":"HLA associations in aurothioglucose-and i-penicilamineinduced haematotoxic reactions in rheumatoid arthritis","volume":"26","author":"Speerstra, F.; Reekers, P.; van de Putte L B A; P, Vandenbroucke J.","year":"1985","unstructured":"Speerstra F, Reekers P, van de Putte L B A, Vandenbroucke J P. HLA associations in aurothioglucose-and i-penicilamineinduced haematotoxic reactions in rheumatoid arthritis. Tissue Antigens 1985; 26: 35-40.","journal-title":"Tissue Antigens"},{"key":"ref_4","first-page":"1326","article-title":"Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs","volume":"fi:","author":"S, Panayi G.; P, Wooley; R, Batchelor J.","year":"1978","unstructured":"Panayi G S, Wooley P, Batchelor J R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J 1978; fi: 1326-8.","journal-title":"Br Med J"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(87)91768-5","article-title":"Gold-induced leucopenia may predict a similar adverse reaction to sulphasalazine","volume":"i:","author":"Bliddal, H.; Eiberg, B.; Helin, P.","year":"1987","unstructured":"Bliddal H, Eiberg B, Helin P. Gold-induced leucopenia may predict a similar adverse reaction to sulphasalazine. Lancet 1987; i: 390.","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1399-0039.1981.tb01391.x","article-title":"HLA-DR phenotype and HLA-B, DR haplotype frequencies in 704 unrelated danes","volume":"18","author":"K, Jacobsen B.; N, Morling; P, Platz; P, Ryder L.; M, Thomsen; A, Svejgaard","year":"1981","unstructured":"Jacobsen B K, Morling N, Platz P, Ryder L P, Thomsen M, Svejgaard A. HLA-DR phenotype and HLA-B,DR haplotype frequencies in 704 unrelated danes. Tissue Antigens 1981; 18: 270-5.","journal-title":"Tissue Antigens"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7326\/0003-4819-101-3-377","article-title":"Sulphasalazine, pharmacology, clinical use, toxicity and related new drug development","volume":"101","author":"A, Peppercorn M.","year":"1984","unstructured":"Peppercorn M A. Sulphasalazine, pharmacology, clinical use, toxicity and related new drug development. Ann Intern Med 1984; 101: 377-86.","journal-title":"Ann Intern Med"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ard.44.3.194","article-title":"Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate","volume":"44","author":"E, Bax D.; S, Amos R.","year":"1985","unstructured":"Bax D E, Amos R S. Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate. Ann Rheum Dis 1985; 44: 194-8.","journal-title":"Ann Rheum Dis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/ard.45.9.761","article-title":"Neutropenia in patients with inflammatory arthritis treated with sulphasalazine","volume":"45","author":"Farr, M.; M, Symmons D.P.; R, Blake D.; A, Bacon P.","year":"1986","unstructured":"Farr M, Symmons D P M, Blake D R, Bacon P A. Neutropenia in patients with inflammatory arthritis treated with sulphasalazine. Ann Rheum Dis 1986; 45: 761-4.","journal-title":"Ann Rheum Dis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/bmj.290.6481.1535","article-title":"Which component of sulphasalazine is active in rheumatoid arthritis?","volume":"290","author":"Pullar, T.; A, Hunter J.; A, Capell H.","year":"1985","unstructured":"Pullar T, Hunter J A, Capell H A. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J 1985; 290: 1535-8.","journal-title":"Br Med J"},{"key":"ref_11","first-page":"178","article-title":"Goldinduced thrombocytopenia","volume":"95","author":"S, Coblyn J.; M, Weinblatt; D, Holdsworth; D, Glass","year":"1981","unstructured":"Coblyn J S, Weinblatt M, Holdsworth D, Glass D. Goldinduced thrombocytopenia. Ann Intern Med 1981; 95: 178-81.","journal-title":"Ann Intern Med"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/art.1780291214","article-title":"HLA-DR antigens in goldinduced neutropenia","volume":"29","author":"Aaron, S.; Davis, P.; Bertouch, J.","year":"1986","unstructured":"Aaron S, Davis P, Bertouch J. HLA-DR antigens in goldinduced neutropenia. Arthritis Rheum 1986; 29: 1515-7.","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724108230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724108230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.48.7.539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T06:16:59Z","timestamp":1738304219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724108230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1989,7]]}},"alternative-id":["S0003496724108230"],"URL":"https:\/\/doi.org\/10.1136\/ard.48.7.539","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[1989,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.48.7.539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/ard.49.6.422-a","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1989 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}